BG65353B1 - Фармацевтичен състав, съдържащ еритропротеин, и използването му за производство на медикаменти - Google Patents

Фармацевтичен състав, съдържащ еритропротеин, и използването му за производство на медикаменти Download PDF

Info

Publication number
BG65353B1
BG65353B1 BG106058A BG10605801A BG65353B1 BG 65353 B1 BG65353 B1 BG 65353B1 BG 106058 A BG106058 A BG 106058A BG 10605801 A BG10605801 A BG 10605801A BG 65353 B1 BG65353 B1 BG 65353B1
Authority
BG
Bulgaria
Prior art keywords
erythropoietin
epo
tissue
molecule
receptor
Prior art date
Application number
BG106058A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG106058A (en
Inventor
Michael Brines
Anthony Cerami
Carla Cerami
Original Assignee
Kenneth S. Warren Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth S. Warren Laboratories filed Critical Kenneth S. Warren Laboratories
Publication of BG106058A publication Critical patent/BG106058A/xx
Publication of BG65353B1 publication Critical patent/BG65353B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BG106058A 1999-04-13 2001-10-26 Фармацевтичен състав, съдържащ еритропротеин, и използването му за производство на медикаменти BG65353B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29093899A 1999-04-13 1999-04-13
US54722000A 2000-04-11 2000-04-11

Publications (2)

Publication Number Publication Date
BG106058A BG106058A (en) 2002-12-29
BG65353B1 true BG65353B1 (bg) 2008-03-31

Family

ID=26966493

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106058A BG65353B1 (bg) 1999-04-13 2001-10-26 Фармацевтичен състав, съдържащ еритропротеин, и използването му за производство на медикаменти

Country Status (21)

Country Link
EP (1) EP1171147A4 (ja)
JP (1) JP2003520194A (ja)
KR (2) KR100883232B1 (ja)
CN (1) CN1607957B (ja)
AU (1) AU784550B2 (ja)
BG (1) BG65353B1 (ja)
BR (1) BR0009737A (ja)
CA (1) CA2383940A1 (ja)
CR (1) CR6501A (ja)
CZ (1) CZ20013695A3 (ja)
EA (1) EA004766B1 (ja)
HU (1) HUP0201598A3 (ja)
IL (2) IL145895A0 (ja)
IS (1) IS6104A (ja)
MX (1) MXPA01010177A (ja)
NO (1) NO20014991L (ja)
NZ (4) NZ545478A (ja)
PL (1) PL352223A1 (ja)
SK (1) SK14412001A3 (ja)
TR (2) TR200103785T2 (ja)
WO (1) WO2000061164A1 (ja)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7304031B2 (en) 2001-10-29 2007-12-04 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
WO2003089468A1 (en) * 2002-04-19 2003-10-30 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
AU2001267882A1 (en) 2000-06-30 2002-01-14 Chugai Seiyaku Kabushiki Kaisha Preventives and remedies for diseases in association with demyelination
DE10043457A1 (de) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
JP2005501801A (ja) * 2001-02-02 2005-01-20 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド フラクトピラノーススルファメートとエリスロポイエチンを含んで成る神経学的機能不全治療
US20030118630A1 (en) * 2001-12-07 2003-06-26 Anthony Cerami Immune modulation device for use in animals
ES2297028T3 (es) 2001-12-07 2008-05-01 Crucell Holland B.V. Produccion de virus, aislados virales y vacunas.
US7335490B2 (en) 2002-01-09 2008-02-26 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure
GB0211578D0 (en) 2002-05-21 2002-06-26 Univ Belfast Medicaments
KR20060019501A (ko) * 2002-07-01 2006-03-03 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 응답 세포, 조직 및 기관을 보호, 회복 및 향상시키기위한 재조합 조직 보호 사이토카인 및 이를 코딩하는 핵산
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US7396913B2 (en) 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
RU2341284C2 (ru) * 2003-03-27 2008-12-20 Янссен Фармацевтика Нв Применение эритропоэтина в восстановлении после инсульта
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
ATE414144T1 (de) 2003-05-09 2008-11-15 Crucell Holland Bv Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon
DE102004004509B4 (de) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
AT500929B1 (de) 2004-11-09 2007-03-15 Medizinische Uni Wien Muw Pharmazeutische zubereitung die erythropoietin enthält
PT2371855E (pt) 2005-08-05 2015-11-03 Araim Pharmaceuticals Inc Péptidos protetores de tecidos e suas utilizações
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
GB0525540D0 (en) * 2005-12-15 2006-01-25 Isis Innovation New treatment
DE102006004008A1 (de) 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
CN101062407A (zh) * 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 ***在预防或治疗视网膜损伤中的用途
US8133860B2 (en) * 2006-07-20 2012-03-13 Rosalind Franklin University Of Medicine And Science Facilitation of resuscitation from cardiac arrest by erythropoietin
CN101610782A (zh) * 2007-01-10 2009-12-23 爱迪生药物公司 使用具有***或血小板生成素活性的化合物治疗呼吸链紊乱
WO2009010107A1 (en) * 2007-07-19 2009-01-22 Hannelore Ehrenreich Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
WO2009094172A2 (en) 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
RU2519695C2 (ru) * 2010-07-21 2014-06-20 Олег Ильич Эпштейн Лекарственное средство для лечения синдрома дефицита внимания и способ лечения синдрома дефицита внимания
CN111066727B (zh) * 2019-12-20 2021-08-27 中国人民解放军陆军军医大学 在低氧性血睾屏障通透中作用机制的小鼠模型构建方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen

Also Published As

Publication number Publication date
EP1171147A4 (en) 2003-05-14
NZ514690A (en) 2004-07-30
CN1607957A (zh) 2005-04-20
AU4348700A (en) 2000-11-14
KR101012932B1 (ko) 2011-02-08
MXPA01010177A (es) 2004-09-10
KR20020000874A (ko) 2002-01-05
BG106058A (en) 2002-12-29
TR200402194T2 (tr) 2004-10-21
NO20014991D0 (no) 2001-10-12
NZ560696A (en) 2010-03-26
NO20014991L (no) 2001-11-15
NZ545478A (en) 2008-04-30
AU784550B2 (en) 2006-05-04
HUP0201598A2 (en) 2002-09-28
CR6501A (es) 2004-04-15
SK14412001A3 (sk) 2002-03-05
CN1607957B (zh) 2012-10-10
BR0009737A (pt) 2003-01-14
IL145895A (en) 2010-05-31
CA2383940A1 (en) 2000-10-19
WO2000061164A1 (en) 2000-10-19
EP1171147A1 (en) 2002-01-16
EA200101073A1 (ru) 2002-10-31
TR200103785T2 (tr) 2002-06-21
HUP0201598A3 (en) 2002-10-28
KR20070094997A (ko) 2007-09-27
IS6104A (is) 2001-10-11
CZ20013695A3 (cs) 2002-02-13
PL352223A1 (en) 2003-08-11
JP2003520194A (ja) 2003-07-02
EA004766B1 (ru) 2004-08-26
IL145895A0 (en) 2002-07-25
NZ533098A (en) 2006-04-28
KR100883232B1 (ko) 2009-02-10

Similar Documents

Publication Publication Date Title
BG65353B1 (bg) Фармацевтичен състав, съдържащ еритропротеин, и използването му за производство на медикаменти
US7309687B1 (en) Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US20080014193A1 (en) Modulation of excitable tissue function by peripherally administered erythropoietin
JP6114099B2 (ja) エリスロポエチン応答性細胞、組織及び器官の保護、回復ならびに増強
US7767643B2 (en) Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
JP2000507939A (ja) 中枢神経系の虚血または外傷後のポリペプチド成長因子の投与
AU2002239665A1 (en) Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
Shults et al. Fibroblast growth factor-2-producing fibroblasts protect the nigrostriatal dopaminergic system from 6-hydroxydopamine
Fallah et al. The effect of a peripheral nerve lesion on calbindin D28k immunoreactivity in the cervical ventral horn of developing and adult rats
AU2006200973A1 (en) Modulation of excitable tissue function by peripherally administered erythropoietin
WO2005084364A2 (en) Long acting tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
UA89468C2 (uk) Модуляція функції тканин, що збуджуються за рахунок периферійного введення еритропоетину
Hilt et al. Early Experiences with Trophic Factors as Drugs for Neurological Disease: Brain-Derived Neurotrophic Factor and Ciliary Neurotrophic Factor for ALS
AU2007200697A1 (en) Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs